放射生物学指导的剂量处方对结直肠癌患者90Y选择性内放射治疗临床获益的影响
本研究纳入23例化疗难治性肝转移结直肠癌患者,将90Y轫致辐射SPECT图像转换为剂量图,分析平均、中位及D70剂量与肿瘤体积变化和 volumetric RECIST 缓解的关系,并用结直肠癌细胞系放射敏感性参数计算生物有效剂量(BED)。结果显示剂量升高与肿瘤体积缩小及缓解概率增加相关,90Y的EBRT等效BED较仅用EBRT参数计算值最多小50%。
要点
- 平均给药放射性活度为1,469 ± 428 MBq(范围847-2,185 MBq),肿瘤平均吸收剂量35.5 ± 9.4 Gy。
- 平均、中位和D70剂量每增加1.0 Gy,肿瘤体积分别缩小1.8%、1.8%和1.5%,volumetric RECIST缓解的比值比分别为1.09、1.09和1.10。
- 缓解的阈值平均、中位和D70剂量分别为48.3、48.8和41.8 Gy。
核心结论
- 剂量学研究假设90Y SIRT与EBRT等效,导致SIRT的BED被高估并可能治疗不足;应用90Y放射生物学参数的BED模型有望改善肿瘤控制评估。
研究设计与样本
- 纳入23例化疗难治性肝转移的转移性结直肠癌(mCRC)患者,将90Y轫致辐射SPECT图像按局部剂量沉积法转换为剂量图。
- 基线和随访CT用于分割肝脏和肿瘤体积,剂量图的平均、中位和D70值与肿瘤体积变化及volumetric RECIST缓解分别用线性和逻辑回归分析。
- 对mCRC细胞系HT-29和DLD-1暴露于90Y或外照射放疗(EBRT;6 MV光子)后的克隆形成实验确定放射敏感性参数,用于BED计算。
主要发现
- 平均给药放射性活度为1,469 ± 428 MBq(范围847-2,185 MBq),肿瘤平均吸收剂量为35.5 ± 9.4 Gy,正常肝脏平均剂量为26.4 ± 6.8 Gy。
- 平均、中位和D70吸收剂量每增加1.0 Gy,肿瘤体积分别缩小1.8%、1.8%和1.5%。
- 平均、中位和D70吸收剂量每增加1.0 Gy,volumetric RECIST缓解概率的比值比分别为1.09、1.09和1.10。
- 缓解的阈值平均、中位和D70剂量分别为48.3、48.8和41.8 Gy。
- 90Y的EBRT等效BED较仅应用EBRT推导的延展校正放射生物学参数计算值最多小50%。
关键数值与推荐
- volumetric RECIST缓解的阈值平均剂量为48.3 Gy。
- volumetric RECIST缓解的阈值中位剂量为48.8 Gy。
- volumetric RECIST缓解的阈值D70剂量为41.8 Gy。
临床怎么用
- 原文结论未据此给出具体临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The purpose of this study was to establish the dose-response relationship of selective internal radiation therapy (SIRT) in patients with metastatic colorectal cancer (mCRC), when informed by radiobiological sensitivity parameters derived from mCRC cell lines exposed to 90Y. Methods: Twenty-three mCRC patients with liver metastases refractory to chemotherapy were included. 90Y bremsstrahlung SPECT images were transformed into dose maps assuming the local dose deposition method. Baseline and follow-up CT scans were segmented to derive liver and tumor volumes. Mean, median, and D70 (minimum dose to 70% of tumor volume) values determined from dose maps were correlated with change in tumor volume and volumetric RECIST response using linear and logistic regression, respectively. Radiosensitivity parameters determined by clonogenic assays of mCRC cell lines HT-29 and DLD-1 after exposure to 90Y or external beam radiotherapy (EBRT; 6 MV photons) were used in biologically effective dose (BED) calculations. Results: Mean administered radioactivity was 1,469 ± 428 MBq (range, 847-2,185 MBq), achieving a mean absorbed radiation dose to tumor of 35.5 ± 9.4 Gy and mean normal liver dose of 26.4 ± 6.8 Gy. A 1.0 Gy increase in mean, median, and D70 absorbed dose was associated with a reduction in tumor volume of 1.8%, 1.8%, and 1.5%, respectively, and an increased probability of a volumetric RECIST response (odds ratio, 1.09, 1.09, and 1.10, respectively). Threshold mean, median and D70 doses for response were 48.3, 48.8, and 41.8 Gy, respectively. EBRT-equivalent BEDs for 90Y are up to 50% smaller than those calculated by applying protraction-corrected radiobiological parameters derived from EBRT alone. Conclusion: Dosimetric studies have assumed equivalence between 90Y SIRT and EBRT, leading to inflation of BED for SIRT and possible undertreatment. Radiobiological parameters for 90Y were applied to a BED model, providing a calculation method that has the potential to improve assessment of tumor control.
引用
- Abbott EM, Falzone N, Lee BQ, et al. The Impact of Radiobiologically Informed Dose Prescription on the Clinical Benefit of 90Y SIRT in Colorectal Cancer Patients. J Nucl Med. 2020. PMID: 32358093. doi:10.2967/jnumed.119.233650
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。